China Proposes Norms For Conditional Approval, Compassionate Use
Executive Summary
Two new proposals by the China FDA will likely accelerate regulatory approvals of novel treatments for life-threatening and rare conditions in the country. By allowing foreign study data, these proposed norms are expected to prompt international drug makers to engage with local regulators early in their global new drug development process.
You may also be interested in...
China Cuts Drug Approval Timelines, Sets Tough Penalties On Individuals Violating R&D Or Safety Rules
Newly released registration proposals signal the Chinese regulator’s intent to foster an environment that is conductive to innovation. Expedited new drug approvals alongside strict control over quality are key elements of these proposals.
China Sets Norms For Foreign Trial Data Submissions
China's latest draft rules set conditions for accepting foreign clinical study data, discouraging ‘selective filing’. Experts see enhanced opportunities for international drug makers to register new products, especially drugs to treat critical, pediatric and rare diseases.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.